No chance IMO they just went over this at the last BYSI CC no offerings needed. Shorts are trapped. Transcript from the last earnings call: "Our cash balance at the end of Q1 was $90.6 million, which we believe will be sufficient to support our ongoing clinical programs over the next year including our immune-oncology pipeline and to prepare for the potential launch of plinabulin in CIN in early 2022."